Human Immunodeficiency Virus Types 1 and 2 Exhibit Comparable Sensitivities to Zidovudine and Other Nucleoside Analog Inhibitors In Vitro-Reference-Cited by-同舟云学术

Human Immunodeficiency Virus Types 1 and 2 Exhibit Comparable Sensitivities to Zidovudine and Other Nucleoside Analog Inhibitors In Vitro

Published:2008-01 Issue:1 Volume:52 Page:329-332
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Smith Robert A.¹,Gottlieb Geoffrey S.²,Anderson Donovan J.¹,Pyrak Crystal L.¹,Preston Bradley D.¹

Affiliation:

1. Departments of Pathology

2. Medicine, University of Washington, Seattle, Washington

Abstract

ABSTRACT Using an indicator cell assay that directly quantifies viral replication, we show that human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2, respectively) exhibit similar sensitivities to 3′-azido-3′-deoxythymidine (zidovudine) as well as other nucleoside analog inhibitors of reverse transcriptase. These data support the use of nucleoside analogs for antiviral therapy of HIV-2 infection.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01004-07

Reference27 articles.

1. Adje-Toure, C. A., R. Cheingsong, J. G. Garcia-Lerma, S. Eholie, M. Y. Borget, J. M. Bouchez, R. A. Otten, C. Maurice, M. Sassan-Morokro, R. E. Ekpini, M. Nolan, T. Chorba, W. Heneine, and J. N. Nkengasong. 2003. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS17(Suppl. 3):S49-S54.

2. Barnett, S. W., H. S. Legg, Y. Sun, J. Klinger, D. J. Blackbourn, C. P. Locher, and J. A. Levy. 1996. Molecular cloning of the human immunodeficiency virus subtype 2 strain HIV-2UC2. Virology222:257-261.

3. Boyer, P. L., S. G. Sarafianos, P. K. Clark, E. Arnold, and S. H. Hughes. 2006. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog.2:101-111.

4. Charneau, P., G. Mirambeau, P. Roux, S. Paulous, H. Buc, and F. Clavel. 1994. HIV-1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol.241:651-662.

5. Cox, S. W., K. Aperia, J. Albert, and B. Wahren. 1994. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res. Hum. Retrovir.10:1725-1729.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress in Nucleoside Antiviral Drugs;Hans Journal of Medicinal Chemistry;2023

2. Derivatives of 3′‐Azidothymidine with 6‐Cyanopyridone as Base or as Phosphoramidate Ester and their Antiretroviral Activity;Helvetica Chimica Acta;2022-12-28

3. Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants;Antimicrobial Agents and Chemotherapy;2019-05

4. The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold;Antiviral Research;2019-02

5. In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2;Antiviral Research;2019-01